Promising breast cancer vaccine could be available by 2030, researchers say

A vaccine designed to prevent and potentially treat triple-negative breast cancer is showing promise in human trials and could be available by 2030.

Cleveland Clinic researchers began exploring a breast cancer vaccine decades ago. In 2018, Anixa Biosciences CEO Dr. Amit Kumar learned of their research and partnered with the Cleveland Clinic to move the vaccine from lab testing toward U.S. Food and Drug Administration approval for human trials.

WATCH: WPTV's Meghan McRoberts' speaks Anixa Biosciences CEO Dr. Amit Kumar

Kumar said the FDA approved testing in women in late 2021, leading to the start of the first trial phase in 2022. Since then, 35 women including one from Florida have participated.

"The data is looking incredibly promising," Kumar said. "In fact, the data that we have see